Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytoplasmic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Cytoplasmic. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-001859-35 Sponsor Protocol Number: cro632 Start Date*: 2007-04-13
    Sponsor Name:Imperial College London
    Full Title: Abatacept in ANCA associated vasculitis: ABAVAS
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017087-17 Sponsor Protocol Number: AL1.0 Start Date*: 2010-09-29
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE).
    Medical condition: ANCA-associated vasculitis (AAV)
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001215-69 Sponsor Protocol Number: 69HCL17_0020 Start Date*: 2018-09-24
    Sponsor Name:Hospices Civils de Lyon
    Full Title: MAINEPSAN Study A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of ...
    Medical condition: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA, Wegener’s) or microscopic polyangiitis (MPA) , 12 months after initiation of treatment for vasculitis onset or flar...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001121-14 Sponsor Protocol Number: CL010_168 Start Date*: Information not available in EudraCT
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculi...
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) DK (Completed) BE (Completed) NO (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005057-36 Sponsor Protocol Number: GLG-801-07 Start Date*: 2018-05-17
    Sponsor Name:GLG Pharma S.A.
    Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant...
    Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038390 Renal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001970-28 Sponsor Protocol Number: CMV-001 Start Date*: 2012-11-20
    Sponsor Name:University of Birmingham
    Full Title: Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-...
    Medical condition: This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis. Specifically the study will investigate the potential for valaciclovir to ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003563-36 Sponsor Protocol Number: ACQUIVAS Start Date*: 2018-07-30
    Sponsor Name:Cambridge University Hospital NHS Foundation Trust and University of Cambridge
    Full Title: ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV)
    Medical condition: Pneumococcal vaccine responses in ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-002846-51 Sponsor Protocol Number: P070703 Start Date*: 2008-07-15
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude de l'efficacité du Rituximab versus Azathioprine en traitement d'entretien au cours des vascularites associées aux ANCA : Etude prospective, multicentrique, contrôlée, randomisée
    Medical condition: Patients atteints de vascularites associées aux ANCA : GW, MPA et formes rénales limitées (glomérulonéphrite pauci-immune), avec ou sans ANCA (au diagnostic comme à la rémission).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-013220-24 Sponsor Protocol Number: Start Date*: 2009-11-02
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomised Controlled Trial
    Medical condition: ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003215-66 Sponsor Protocol Number: MARAVITRANS Start Date*: 2012-09-26
    Sponsor Name:FIBio Hospital Universitario Ramón y Cajal
    Full Title: EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD
    Medical condition: HIV-infected patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005535-24 Sponsor Protocol Number: ABROGATE-5527 Start Date*: 2016-06-07
    Sponsor Name:Univeristy of South Florida
    Full Title: Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's)
    Medical condition: Granulomatosis with polyangiitis (GPA; Wegener's granulomatosis)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10047889 Wegeners granulomatosis LLT
    19.0 100000004866 10047888 Wegener's granulomatosis LLT
    19.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001222-15 Sponsor Protocol Number: CL002_168 Start Date*: 2011-07-20
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Bac...
    Medical condition: Non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvement
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) PL (Completed) AT (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001102-14 Sponsor Protocol Number: Ritazarem Start Date*: Information not available in EudraCT
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis
    Medical condition: ANCA vasculitis.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10047889 Wegeners granulomatosis LLT
    15.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis PT
    15.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001663-33 Sponsor Protocol Number: MYCYC Start Date*: 2007-12-06
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis
    Medical condition: Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001174-33 Sponsor Protocol Number: 28612 Start Date*: 2008-12-30
    Sponsor Name:Merck Serono International S.A., A branch of Laboratoires Serono S.A.
    Full Title: A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® ...
    Medical condition: Females undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021930 Infertility NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002888-33 Sponsor Protocol Number: P150964 Start Date*: 2017-01-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001328-17 Sponsor Protocol Number: IMIB-HTF-2021-01 Start Date*: 2021-09-23
    Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia
    Full Title: Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1.
    Medical condition: Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003884-12 Sponsor Protocol Number: EXTRAStudy Start Date*: 2015-12-22
    Sponsor Name:AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
    Full Title: A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy on glomerular proliferative lesions in patients with ext...
    Medical condition: Extracapillary glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018376 Glomerulonephritis proliferative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000381-34 Sponsor Protocol Number: CL019_168 Start Date*: 2023-05-30
    Sponsor Name:ChemoCentryx
    Full Title: An Open Label, Randomized, Crossover, Single Dose Bioavailability Study in Healthy Adult Subjects to Evaluate the Pharmacokinetic Profile of an Exploratory Avacopan Pediatric Liquid Formulation Com...
    Medical condition: Anti-Neutrophil Cytoplasmic Antibody associated vasculitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000225-12 Sponsor Protocol Number: CNTO148DML1001 Start Date*: 2017-08-01
    Sponsor Name:Janssen Biologics BV
    Full Title: A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes
    Medical condition: A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:30:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA